Evidence map›Paper›PMID 41290257›Full record

ArticleJournal for immunotherapy of cancer2025

HMGA2 links morphological evolution and microenvironment dynamics to systemic therapy response in clear cell renal cell carcinoma.

Takahiro Nakamoto, Takashi Yoshida, Chisato Ohe, Yoshiki Yasukochi, Naho Atsumi, Takeshi Sano, Koichiro Higasa, Katsunori Uchida, Koji Tsuta, Hidefumi Kinoshita

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Takahiro NakamotoDepartment of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan.ORCID http://orcid.org/0009-0006-7540-1812
Takashi YoshidaDepartment of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan yoshidtk@takii.kmu.ac.jp.ORCID http://orcid.org/0000-0003-1119-312X
Chisato OheDepartment of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan.
Yoshiki YasukochiDepartment of Genome Analysis, Institute of Biomedical Science, Kansai Medical University, Hirakata, Osaka, Japan.
Naho AtsumiDepartment of Pathology, Kansai Medical University, Hirakata, Osaka, Japan.
Takeshi SanoDepartment of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan.
Koichiro HigasaDepartment of Genome Analysis, Institute of Biomedical Science, Kansai Medical University, Hirakata, Osaka, Japan.
Katsunori UchidaDepartment of Pathology, Kansai Medical University, Hirakata, Osaka, Japan.
Koji TsutaDepartment of Pathology, Kansai Medical University, Hirakata, Osaka, Japan.
Hidefumi KinoshitaDepartment of Urology and Andrology, Kansai Medical University, Hirakata, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClear cell renal cell carcinoma (ccRCC) exhibits significant heterogeneity due to morphological changes and tumor microenvironment dynamics, influencing systemic therapy responses. While the role of high-mobility group AT-hook 2 (HMGA2) in tumor progression has been implicated in other cancers, its significance in ccRCC remains unclear. This study investigates the role of HMGA2 in these processes and its clinical impact.

methodsSpatial transcriptomics (ST) was performed on primary ccRCC samples to investigate expression trajectories associated with

resultsHMGA2 expression was associated with aggressive morphological patterns, such as solid sheets and rhabdoid/sarcomatoid. ST revealed a progressive increase in

conclusionsThese findings suggest that dynamic HMGA2 expression contributes to morphological evolution and modulates immune responses through enhanced Tpex-cDCs engagement, serving as a potential marker for systemic therapy response in ccRCC. However, additional experimental studies are required to validate these mechanisms.

Indexed as

Carcinoma, Renal CellHMGA2 ProteinTumor MicroenvironmentCD8-Positive T-LymphocytesCell CycleDendritic CellsDisease ProgressionDrug Therapy, CombinationEpithelial-Mesenchymal TransitionHumansImmune Checkpoint InhibitorsSignal TransductionSingle-Cell Gene Expression AnalysisSpatial TranscriptomicsHMGA2 ProteinHMGA2 protein, humanImmune Checkpoint InhibitorsImmune Checkpoint InhibitorKidney CancerPathology

Identifiers

PMID41290257
PMCPMC12645796

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.